Group | Data set | All tumour stages | Resectable tumours, stages IA–IIB | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | AUC (95% CI) | Bio marker cut-off | Sensitivity (95% CI) % | Specificity (95% CI) % | PPV (95% CI) % | NPV (95% CI) % | Accuracy (95% CI) % | n | Sensitivity (95% CI) % | Specificity (95% CI) % | Accuracy (95% CI) % | ||
PDAC versus CP | Training | 78/80 | 0.96 (0.93 to 0.98) | 0.384 | 94.9 (87.0 to 97.0) | 85 | 11.2 (10.3 to 11.4) | 99.9 (99.7 to 99.93) | 90.0 (86.0 to 91.0) | 55/80 | 98.2 (93.3 to 99.4) | 85 | 91.6 (89.2 to 92.2) |
Test | 79/80 | 0.94 (0.91 to 0.97) | 0.384 | 89.9 (81.0 to 95.5) | 91.3 (82.8 to 96.4) | 17.0 (9.5 to 29.4) | 99.8 (99.6 to 99.9) | 90.6 (84.9 to 94.6) | 40/80 | 90.0 (76.3 to 97.2) | 91.3 (82.8 to 96.4) | 90.8 (84.2 to 95.3) |
AUC, area under the curve; CP, chronic pancreatitis; NPV, negative predictive value; PDAC, pancreatic adenocarcinoma; PPV, positive predictive value.